Willis Towers Watson CapEx decreased by 12.7% to $55.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $51.00M to $55.00M. Over 2 years (FY 2023 to FY 2025), CapEx shows relatively stable performance with a -2.7% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $60.50M | $60.50M | $60.50M | $60.50M | $60.00M | $66.00M | $63.00M | $56.00M | $51.00M | $58.00M | $57.00M | $63.00M | $55.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -0.8% | +10.0% | -4.5% | -11.1% | -8.9% | +13.7% | -1.7% | +10.5% | -12.7% |
| YoY Change | — | — | — | — | -0.8% | +9.1% | +4.1% | -7.4% | -15.0% | -12.1% | -9.5% | +12.5% | +7.8% |